



FORM 7
MONTHLY PROGRESS REPORT FOR THE MONTH ENDED NOVEMBER 30, 2019

Name of Listed Issuer: MPX International Corporation (“MPXI” or the “Issuer”).

Trading Symbol: MPXI

Number of Outstanding Listed securities: 135,144,487

Date: December 6, 2019

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are “material information” as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) *Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.*
- (b) *The term “Issuer” includes the Issuer and any of its subsidiaries.*
- (c) *Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.*

Report on Business

- 1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

MPX Australia Awarded Cannabis Manufacture Licence

On November 6, 2019, the Issuer announced that its wholly-owned subsidiary MPX Australia Pty Ltd was issued a Cannabis Manufacture Licence by the Australian Office of Drug Control.

Launch of "beleaf" Premium CBD Retail Experience in the United Kingdom

On November 7, 2019, the Issuer announced that its United Kingdom premium CBD retail experience opened in the Soho district of Central London under the name "beleaf".

Focused on providing quality, organic and ethically-sourced products in an upscale retail setting, beleaf offers a broad range of premium brand extracts, cosmetics, vapes and edibles with initially more than 100 product lines available for sale. An emphasis on providing education will help counsel CBD curious consumers; physical in-store displays, digital kiosks and online resources will be complemented by on-site cannabis specialists available to address queries and help guide purchasing decisions. The location also features a 'blends bar' and lounge where customers can sample various CBD-infused products.

The Issuer is working in partnership with the retail developer, iD agency. With extensive experience creating and managing unique, effective and immersive retail environments, iD agency will manage the beleaf store and promotional events.

- 2. Provide a general overview and discussion of the activities of management.**

Reference is made to Item (1) above, the Issuer's page on the CSE website and its profile at www.sedar.com.

- 3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.**

Reference is made to Item (1) above, the Issuer's page on the CSE website and its profile at www.sedar.com.

- 4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.**

None.

- 5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements**

and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Reference is made to Item (1) above, the Issuer's page on the CSE website and its profile at www.sedar.com.

- 6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.**

None.

- 7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.**

None.

- 8. Describe the acquisition of new customers or loss of customers.**

None.

- 9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.**

Reference is made to Item (1) above, the Issuer's page on the CSE website and its profile at www.sedar.com.

- 10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.**

None.

- 11. Report on any labour disputes and resolutions of those disputes if applicable.**

None.

- 12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

None.

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The Issuer is focused on developing and operating assets across the global cannabis industry with an emphasis on cultivating, manufacturing and marketing products which include cannabinoids as their primary active ingredient.

The Issuer will concentrate on developing its assets in Canada, while continuing to evaluate and develop opportunities in the European Union, United Kingdom, Australia and South Africa.

In its Summer 2018 edition of the European Cannabis Report, the leading industry advisory firm, Prohibition Partners estimated that the European cannabis market would grow to €115 billion (US\$177 billion) by 2028, virtually double the size of the forecast U.S. market. The same firm's estimate in its November issue of the Oceania Cannabis Report projected that total market size in Australia and Oceania to be approximately US\$23 billion (including CBD products). These markets are in the early stages of development compared to the industry in North America and the Issuer will focus on establishing early-mover advantage as the regulations in the respective countries continue to evolve. The Issuer continues to have the support of a large contingent of international shareholders, which it believes will strengthen its international expansion efforts. The Issuer will spend time partnering with advisory and industry support groups across several countries and expects to be in a position to leverage managements relationship with key industry suppliers, leaving it well-positioned to take a quick foothold in these emerging cannabis markets.

According to a report released by the Brightfield Group, a research firm that provides data on legal CBD and Cannabis industries, the European CBD market is expected to hit \$416 million in 2019 and expected to grow 400% to \$1.7 billion in 2023.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated December 6, 2019.

Jeremy S. Budd
Name of Director or Senior Officer

signed "Jeremy S. Budd"
Signature

Executive VP, General Counsel,
Corporate Secretary and a director
Official Capacity

Issuer Details		<i>For Month End</i>	<i>Date of Report</i>
<i>Name of Issuer</i> MPX International Corporation		December 2019	YY/MM/DD 19/12/06
<i>Issuer Address</i> 5255 Yonge Street, Suite 701			
<i>City/Province/Postal Code</i>	<i>Issuer Fax No.</i>	<i>Issuer Telephone No.</i>	
Toronto, Ontario, M2N 6P4	1-877-595-1828	(416) 840-3725	
<i>Contact Name</i>	<i>Contact Position</i>	<i>Contact Telephone No.</i>	
W. Scott Boyes	Chairman, President and CEO	(416) 840-3725	
<i>Contact Email Address</i> info@mpxinternationalcorp.com		<i>Web Site Address</i> www.mpxinternationalcorp.com	